CAVERJECT 20 MCG

국가: 이스라엘

언어: 영어

출처: Ministry of Health

지금 구매하세요

환자 정보 전단 환자 정보 전단 (PIL)
17-08-2016
제품 특성 요약 제품 특성 요약 (SPC)
22-08-2023
공공 평가 보고서 공공 평가 보고서 (PAR)
11-04-2021

유효 성분:

ALPROSTADIL

제공처:

PFIZER PFE PHARMACEUTICALS ISRAEL LTD

ATC 코드:

G04BE01

약제 형태:

POWDER FOR SOLUTION FOR INJECTION

구성:

ALPROSTADIL 20 MCG/VIAL

관리 경로:

INTRACAVERNOSAL

처방전 유형:

Required

Manufactured by:

PFIZER MANUFACTURING BELGIUM NV/SA

치료 그룹:

ALPROSTADIL

치료 영역:

ALPROSTADIL

치료 징후:

Treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic or mixed etiology. Useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

승인 날짜:

2020-06-30

환자 정보 전단

                                ةعرجلا صحف
.امامت كتعرجل ةمئلاملا ةملاعلا لباقم
سبكملا نوكي ىتح طغضلا لصاو
.ةملاعلا رهظت نيأ بيبطلا كل حضوأ دقل
لولحملا نقح II مسقلا
.هاندأ امهفصو دراولا ( corpora cavernosa)
نيتقطنملا ىدحإ يف زهاجلا لولحملا نقح
ُ
ي
•
.نلآا اهحتفا ،ةيناثلا ميقعتلا ةشاش
لامعتساب بيبطلا كل ىصوأ اذإ .احاترم
نوكت يكل دعتساو كسبلام عزنا
•
وضعلا يف اهنم ءزج ءاقبو ةربإ رسك نع
تاغيلبت كانه .رسكلل ادج ةضرعم ةيوتلملا
ةربلإا .ةيوتلم تسيل ةربلإا نأ نم دكأت
تضرعت اذإ .ةيحارج ةيلمعب مسجلا نم
ةربلإا ةلازإو ىفشتسملا يف ثوكملا ىلإ
ةجاح كانه تناك ةنيعم تلااح يفو ،يركذلا
ةربلإا لعج ةلواحم زوجي لا .ربلإا ربع
بقثلل ةمواقم ةقلغم ةيواح يف اهنم
صلختلا بجيو اهلامعتسا زوجي لا
،ءاوتللال ةربلإا
يف رهظي امك فطلب طغضاو ةبابسلاو
ماهبلإاب ةفلقلا كسمأ .ةنقحملا ىلع
،ةلمعتسم ريغ ،ةديدج ةمقعم ةربإ تبث
.ةميقتسم
.جراخلا وحن نقحلا ةقطنم زربت .C مسرلا
•
ىلع فطلب طغضا .هقوف ماهبلإاو ،نيتيصخلا
نم برقلاب هتحت نيعبصإ نوكي امنيب
،ةيماملأا ةهجلا نم يركذلا وضعلا كسمأ
.فلخلا وحن ةفلقلا بحسا ،ناتخلا ةيلمع
زتجت مل اذإ .نقحلا ةقطنم زاربلإ
ةبابسلاو ماهبلإا نيب يركذلا وضعلا
•
. A مسرلا رظنا ،ةنكادلا ةقطنملا يف
نقحلا ةيلمع متت
•
.فجت ةقطنملا عدو ةيناثلا ميقعتلا ةشاشب
نقحلا ةقطنم ر
ّ
هط ،بيبطلا
                                
                                전체 문서 읽기
                                
                            

제품 특성 요약

                                Caverject LPD CC 150623
Page 1 of ; 2023-0086474
_ _
_ _
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Caverject 10 micrograms
Caverject 20 micrograms
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Alprostadil 10 micrograms.
When reconstituted, each 1ml delivers a dose of 10 micrograms of
alprostadil.
Alprostadil 20 micrograms.
When reconstituted, each 1ml delivers a dose of 20 micrograms of
alprostadil.
Alprostadil 10 micrograms & 20 micrograms:
Excipient with known effect:
Each 1ml of reconstituted solution contains 8.4 mg of benzyl alcohol,
equivalent to 8.4 mg/ml.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for Solution for Injection
A white to off-white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Caverject is indicated for the treatment of erectile dysfunction in
adult males, due to
neurogenic, vasculogenic, psychogenic or mixed aetiology.
Caverject may be a useful adjunct to other diagnostic tests in the
diagnosis of erectile
dysfunction.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Caverject is administered by direct intracavernous injection. A half
inch, 27 to 30 gauge
needle is generally recommended. The dose of Caverject should be
individualised for
each patient by careful titration under supervision by a physician.
The intracavernosal injection must be done under sterile conditions.
The site of injection
is usually along the dorsolateral aspect of the proximal third of the
penis. Visible veins
should be avoided. Both the side of the penis that is injected and the
site of injection must
Caverject LPD CC 150623
Page 2 of ; 2023-0086474
be alternated; prior to the injection, the injection site must be
cleansed with an alcohol
swab.
To reconstitute Caverject using the prefilled diluent syringe: flip
off the plastic cap from
the vial, and use one of the swabs to wipe the rubber cap. Fit the 22
gauge needle to the
syringe.
Inject the 1 ml of diluent into the vial, and shake to dissolve the
powder entirely.
Withdraw slightly more than the req
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 아랍어 20-12-2021
환자 정보 전단 환자 정보 전단 히브리어 17-08-2016

이 제품과 관련된 검색 알림